How I treat splenomegaly in myelofibrosis

por Cervantes, F
Publicado 2011

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

por Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T
Publicado 2016

Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

por Harrison, C N, Vannucchi, A M, Kiladjian, J-J, Al-Ali, H K, Gisslinger, H, Knoops, L, Cervantes, F, Jones, M M, Sun, K, McQuitty, M, Stalbovskaya, V, Gopalakrishna, P, Barbui, T
Publicado 2017

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS

por Kiladjian, J.-J., Tefferi, A., Passamonti, F., Vannucchi, A., Talpaz, M., Cervantes, F., Harrison, C. N., Mesa, R. A., Mascarenhas, J., Schaap, N., Verstovsek, S., Devos, T., Rose, S., Zhang, J., Sy, O., Pardanani, A.
Publicado 2022

P1026: COMPARATIVE GENOMIC PROFILING OF MYELOPROLIFERATIVE NEOPLASMS PRESENTING WITH AND WITHOUT SPLANCHNIC VEIN THROMBOSIS

por Garrote, M., López-Guerra, M., Arellano-Rodrigo, E., Magaz, M., Triguero, A., Carbonell, S., Alamo, J. R., Turon, F., Hernandez-Gea, V., Baiges, A., Colomer, D., García-Pagán, J. C., Cervantes, F., Alvarez-Larrán, A.
Publicado 2022

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium

por Tefferi, A, Abdel-Wahab, O, Cervantes, F, Crispino, J D, Finazzi, G, Girodon, F, Gisslinger, H, Gotlib, J, Kiladjian, J-J, Levine, R L, Licht, J D, Mullally, A, Odenike, O, Pardanani, A, Silver, R T, Solary, E, Mughal, T
Publicado 2011

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

por Hughes, T P, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N C D, Schwarer, A P, Dorlhiac-Llacer, P E, Mahon, F-X, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S, Lipton, J H
Publicado 2017

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients

por De Stefano, V, Vannucchi, A M, Ruggeri, M, Cervantes, F, Alvarez-Larrán, A, Iurlo, A, Randi, M L, Pieri, L, Rossi, E, Guglielmelli, P, Betti, S, Elli, E, Finazzi, M C, Finazzi, G, Zetterberg, E, Vianelli, N, Gaidano, G, Nichele, I, Cattaneo, D, Palova, M, Ellis, M H, Cacciola, E, Tieghi, A, Hernandez-Boluda, J C, Pungolino, E, Specchia, G, Rapezzi, D, Forcina, A, Musolino, C, Carobbio, A, Griesshammer, M, Barbui, T
Publicado 2016

P995: MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT

por Mora, B., Guglielmelli, P., Kuykendall, A., Maffioli, M., Rotunno, G., Komrokji, R. S., Palandri, F., Kiladjian, J.-J., Iurlo, A., Auteri, G., Cattaneo, D., De Stefano, V., Salmoiraghi, S., Devos, T., Cervantes, F., Merli, M., Campagna, A., Benevolo, G., Brociner, M., Albano, F., Gotlib, J., Caramella, M., Ruggeri, M., Ross, D. M., Orsini, F., Pessina, C., Colugnat, I., Pallotti, F., Barbui, T., Bertù, L., Della Porta, M. G., Vannucchi, A. M., Passamonti, F.
Publicado 2022

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

por Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., Hjorth-Hansen, H., Hughes, T. P., Janssen, J. J. W. M., Kantarjian, H. M., Kim, D. W., Larson, R. A., Lipton, J. H., Mahon, F. X., Mayer, J., Nicolini, F., Niederwieser, D., Pane, F., Radich, J. P., Rea, D., Richter, J., Rosti, G., Rousselot, P., Saglio, G., Saußele, S., Soverini, S., Steegmann, J. L., Turkina, A., Zaritskey, A., Hehlmann, R.
Publicado 2020